Tissue Microarrays (TMA)
TMAs in Clinical Studies
TMD utilizes TMA technology to analyze many biomarkers simultaneously. Dozens to hundreds of punch cores from tumor specimens are arrayed onto a single slide.
A TMA is a same environment, high throughput method of biomarker expression profiling. Each TMA slide is processed on an automated staining platform to ensure consistency and reproducibility. This enables TMD to assist companies engaged in drug development to quickly assess which biomarkers are best suited for their drug or cancer type. TMD’s team of scientists, under the direction of Dr. Sarah Bacus, provides expert guidance in biomarker validation using this technology. Because large panels of biomarkers are often undesirable for Phase III trials, TMAs help define the most information rich biomarkers.
TMD published a TMA analysis of biomarkers of response and resistance to Herceptin therapy in: Br J Canc (2004)91:1190-94.
Click to enlarge >>
Examples of a negative and positive core stained for either IGF-1R or Phospho-S6 ribosomal protein.
Key Benefits
• |
TMD sources appropriate TMAs according to project specifications |
• |
TMAs are stained using automated IHC to ensure consistency of results |
• |
Each core is scored by a board-certified pathologist and intensity is reported for nuclear, cytoplasmic, and membrane staining |
To learn how the application of tissue microarrays will benefit your current study, review TMD’s Breakthrough Article on Tissue Microarrays.
To consult with TMD’s Translational Biomarker Specialists, call 866.897.7350 ex 213 or email TMD Translational Biomarker Services at biomarkers@tmdlab.com.
|
